FDA's TEMPO Pilot Lets Some AI Medical Devices Reach Patients Before Full Authorization

The FDA has accepted four generative AI medical devices, including products from Cadence and Limbic, into its TEMPO pilot program. This pathway allows digital health companies to deploy products to patients without first obtaining standard marketing authorization, under a structured oversight framework.

Why it matters

The FDA's TEMPO pilot represents a deliberate shift in how the agency approaches generative AI medical devices. Rather than requiring full pre-market authorization before any patient exposure, TEMPO creates a structured pathway for conditional deployment, with ongoing data collection and oversight built into the arrangement. Four devices have been accepted so far, including Cadence, which focuses on remote patient monitoring, and Limbic, which operates in mental health support.

The practical implication for health system leaders is that the regulatory landscape for AI tools is no longer a simple binary of authorized or not. Procurement teams, clinical informatics leaders, and risk officers need frameworks for evaluating TEMPO-enrolled products on their own terms, asking hard questions about what evidence exists, what monitoring is in place, and what the institution's exposure looks like if something goes wrong before full authorization is granted.

What to watch

Whether health systems and payers establish their own internal authorization standards for TEMPO-enrolled devices, rather than defaulting to FDA pilot acceptance as a proxy for readiness.